Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017, Article ID 2438247, 11 pages
https://doi.org/10.1155/2017/2438247
Research Article

Maresin 1 Mitigates High Glucose-Induced Mouse Glomerular Mesangial Cell Injury by Inhibiting Inflammation and Fibrosis

1Endocrinology Department, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China
2The Graduate School of Southwest Medical University, Luzhou, Sichuan 646000, China
3State Key Laboratory of Quality Research in Chinese Medicine, Faculty of Chinese Medicine, Macau University of Science and Technology, Avenida Wai Long, Taipa, Macau

Correspondence should be addressed to Yong Xu; moc.nuyila@llywyx

Received 9 October 2016; Revised 6 December 2016; Accepted 19 December 2016; Published 15 January 2017

Academic Editor: Dah-Yuu Lu

Copyright © 2017 Shi Tang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Y. Donath, “Targeting inflammation in the treatment of type 2 diabetes: time to start,” Nature Reviews Drug Discovery, vol. 13, no. 6, pp. 465–476, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. Y. S. Kanwar, L. Sun, P. Xie, F. Liu, and S. Chen, “A glimpse of various pathogenetic mechanisms of diabetic nephropathy,” Annual Review of Pathology: Mechanisms of Disease, vol. 6, pp. 395–423, 2011. View at Publisher · View at Google Scholar
  3. J. Wada and H. Makino, “Inflammation and the pathogenesis of diabetic nephropathy,” Clinical Science, vol. 124, no. 3, pp. 139–152, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. P. M. García-García, M. A. Getino-Melián, V. Domínguez-Pimentel, and J. F. Navarro-González, “Inflammation in diabetic kidney disease,” World Journal of Diabetes, vol. 5, no. 4, pp. 431–443, 2014. View at Publisher · View at Google Scholar
  5. S. C. W. Tang, G. C. W. Chan, and K. N. Lai, “Recent advances in managing and understanding diabetic nephropathy,” F1000Research, vol. 5, Article ID F1000 Faculty Rev-1044, 2016. View at Publisher · View at Google Scholar
  6. D. De Nardo and E. Latz, “NLRP3 inflammasomes link inflammation and metabolic disease,” Trends in Immunology, vol. 32, no. 8, pp. 373–379, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Wang, Y. Pan, Q.-Y. Zhang, F.-M. Wang, and L.-D. Kong, “Quercetin and allopurinol ameliorate kidney injury in STZ-treated rats with regulation of renal NLRP3 inflammasome activation and lipid accumulation,” PLoS ONE, vol. 7, no. 6, Article ID e38285, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Bryant and K. A. Fitzgerald, “Molecular mechanisms involved in inflammasome activation,” Trends in Cell Biology, vol. 19, no. 9, pp. 455–464, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. F. G. Bauernfeind, G. Horvath, A. Stutz et al., “Cutting edge: NF-κB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression,” Journal of Immunology, vol. 183, no. 2, pp. 787–791, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. H.-M. Lee, J.-J. Kim, H. J. Kim, M. Shong, B. J. Ku, and E.-K. Jo, “Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes,” Diabetes, vol. 62, no. 1, pp. 194–204, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Wada and H. Makino, “Innate immunity in diabetes and diabetic nephropathy,” Nature Reviews Nephrology, vol. 12, no. 1, pp. 13–26, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Qiu and L. Tang, “Roles of the NLRP3 inflammasome in the pathogenesis of diabetic nephropathy,” Pharmacological Research, vol. 114, no. 5, pp. 251–264, 2016. View at Publisher · View at Google Scholar
  13. Y. A. Samra, H. S. Said, N. M. Elsherbiny, G. I. Liou, M. M. El-Shishtawy, and L. A. Eissa, “Cepharanthine and Piperine ameliorate diabetic nephropathy in rats: role of NF-κB and NLRP3 inflammasome,” Life Sciences, vol. 157, pp. 187–199, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Li, Y. S. Kang, C. Dai, L. P. Kiss, X. Wen, and Y. Liu, “Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria,” The American Journal of Pathology, vol. 172, no. 2, pp. 299–308, 2008. View at Publisher · View at Google Scholar
  15. H. Y. Lan, “Diverse roles of TGF-β/Smads in renal fibrosis and inflammation,” International Journal of Biological Sciences, vol. 7, no. 7, pp. 1056–1067, 2011. View at Google Scholar · View at Scopus
  16. L. Liu, Y. Wang, R. Yan et al., “Oxymatrine inhibits renal tubular EMT induced by high glucose via upregulation of SnoN and inhibition of TGF-β1/Smad signaling pathway,” PLOS ONE, vol. 11, no. 3, Article ID e0151986, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. A. P. Simopoulos, “Omega-3 fatty acids in inflammation and autoimmune diseases,” Journal of the American College of Nutrition, vol. 21, no. 6, pp. 495–505, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. C. N. Serhan, “Pro-resolving lipid mediators are leads for resolution physiology,” Nature, vol. 510, no. 7503, pp. 92–101, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Dalli, M. Zhu, N. A. Vlasenko et al., “The novel 13S,14S-epoxy-maresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts macrophage phenotype,” FASEB Journal, vol. 27, no. 7, pp. 2573–2583, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Chatterjee, A. Sharma, M. Chen, R. Toy, G. Mottola, and M. S. Conte, “The pro-resolving lipid mediator maresin 1 (MaR1) attenuates inflammatory signaling pathways in vascular smooth muscle and endothelial cells,” PLoS ONE, vol. 9, no. 11, Article ID e113480, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Wang, R. Li, L. Chen et al., “Maresin 1 inhibits epithelial-to-mesenchymal transition in vitro and attenuates bleomycin induced lung fibrosis in vivo,” Shock, vol. 44, no. 5, pp. 496–502, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. T. M. Nordgren, A. J. Heires, T. A. Wyatt et al., “Maresin-1 reduces the pro-inflammatory response of bronchial epithelial cells to organic dust,” Respiratory Research, vol. 14, no. 1, article 51, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. C. N. Serhan, J. Dalli, S. Karamnov et al., “Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain,” FASEB Journal, vol. 26, no. 4, pp. 1755–1765, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. X. Sun, X. Jiao, Y. Ma et al., “Trimethylamine N-oxide induces inflammation and endothelial dysfunction in human umbilical vein endothelial cells via activating ROS-TXNIP-NLRP3 inflammasome,” Biochemical and Biophysical Research Communications, vol. 481, no. 1-2, pp. 63–70, 2016. View at Publisher · View at Google Scholar
  25. A. Eftekhari, E. Ahmadian, Y. Azarmi, A. Parvizpur, H. Hamishehkar, and M. A. Eghbal, “In vitro/vivo studies towards mechanisms of risperidone-induced oxidative stress and the protective role of coenzyme Q10 and N-acetylcysteine,” Toxicology Mechanisms and Methods, vol. 26, no. 7, pp. 1–9, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Liu, C. Gao, G. Chen et al., “Notch signaling molecules activate TGF-β in rat mesangial cells under high glucose conditions,” Journal of Diabetes Research, vol. 2013, Article ID 979702, 8 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Gao, G. Chen, L. Liu et al., “Impact of high glucose and proteasome inhibitor MG132 on histone H2A and H2B ubiquitination in rat glomerular mesangial cells,” Journal of Diabetes Research, vol. 2013, Article ID 589474, 10 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. X. Chen, D.-D. Wang, T. Wei, S.-M. He, G.-Y. Zhang, and Q.-L. Wei, “Effects of astragalosides from Radix Astragali on high glucose-induced proliferation and extracellular matrix accumulation in glomerular mesangial cells,” Experimental and Therapeutic Medicine, vol. 11, no. 6, pp. 2561–2566, 2016. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Börgeson and C. Godson, “Resolution of inflammation: therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications,” Frontiers in Immunology, vol. 3, article no. 318, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. C. N. Serhan, R. Yang, K. Martinod et al., “Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions,” Journal of Experimental Medicine, vol. 206, no. 1, pp. 15–23, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Sasaki, D. Urabe, H. Arai, M. Arita, and M. Inoue, “Total synthesis and bioactivities of two proposed structures of maresin,” Chemistry - An Asian Journal, vol. 6, no. 2, pp. 534–543, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Viola, P. Lemnitzer, Y. Jansen et al., “Resolving lipid mediators maresin 1 and resolvin D2 prevent atheroprogression in mice,” Circulation Research, vol. 119, no. 9, pp. 1030–1038, 2016. View at Publisher · View at Google Scholar
  33. J. Gong, Z.-Y. Wu, H. Qi et al., “Maresin 1 mitigates LPS-induced acute lung injury in mice,” British Journal of Pharmacology, vol. 171, no. 14, pp. 3539–3550, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. R. Li, Y. Wang, E. Zhao et al., “Maresin 1, a proresolving lipid mediator, mitigates carbon tetrachloride-induced liver injury in mice,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 9203716, 13 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Hong, Y. Lu, H. Tian et al., “Maresin-like lipid mediators are produced by leukocytes and platelets and rescue reparative function of diabetes-impaired macrophages,” Chemistry and Biology, vol. 21, no. 10, pp. 1318–1329, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Volpe, P. Anjos, and J. Nogueira-Machado, “Inflammasome as a new therapeutic target for diabetic complications,” Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, vol. 10, no. 1, pp. 56–62, 2016. View at Publisher · View at Google Scholar
  37. K. Schroder and J. Tschopp, “The inflammasomes,” Cell, vol. 140, no. 6, pp. 821–832, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. C.-S. Yang, D.-M. Shin, and E.-K. Jo, “The role of NLR-related protein 3 inflammasome in host defense and inflammatory diseases,” International Neurourology Journal, vol. 16, no. 1, pp. 2–12, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. R. Zhou, A. Tardivel, B. Thorens, I. Choi, and J. Tschopp, “Thioredoxin-interacting protein links oxidative stress to inflammasome activation,” Nature Immunology, vol. 11, no. 2, pp. 136–140, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. H. L. Hutton, J. D. Ooi, S. R. Holdsworth, and A. R. Kitching, “The NLRP3 inflammasome in kidney disease and autoimmunity,” Nephrology, vol. 21, no. 9, pp. 736–744, 2016. View at Publisher · View at Google Scholar · View at Scopus
  41. H. Feng, J. Gu, F. Gou et al., “High glucose and lipopolysaccharide prime NLRP3 inflammasome via ROS/TXNIP pathway in mesangial cells,” Journal of Diabetes Research, vol. 2016, Article ID 6973175, 11 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  42. H. W. Schnaper, T. Hayashida, S. C. Hubchak, and A.-C. Poncelet, “TGF-β signal transduction and mesangial cell fibrogenesis,” American Journal of Physiology - Renal Physiology, vol. 284, no. 2, pp. F243–F252, 2003. View at Publisher · View at Google Scholar · View at Scopus